In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Lina Eliasson PhD CPsycho, Founding Partner at Sprout Health Solutions, to discuss how pharma companies of all sizes can build a comprehensive, patient-centric evidence strategy that spans the entire drug development pathway. Together, they examine the growing role of COA and in-study interviews in regulatory decision-making, the practical barriers to earlier patient engagement. They explore how eCOA providers could add greater value by getting involved long before a pivotal trial, and a focus on why the choice of data capture modality matters far more than the industry currently recognizes.
Artificial intelligence is redefining what’s possible across the clinical development lifecycle, but with rapid innovation comes the need for thoughtful oversight. In this episode...
In this episode of TransPerfect LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences sits down with Andrew Lloyd, Director at Acaster-Lloyd...
Explore how artificial intelligence is rapidly changing the landscape of clinical trials, from discovering new therapies and complex calculations to protocol optimization. Discover how...
